Gapping up
In reaction to strong earnings/guidance: OXM +10.2%, OLLI +9.2%, PI +7.9%, NTEC +5.1%, SMTC +1.9%, APOP+1.8%, GEF +1.5%
M&A news:
In reaction to strong earnings/guidance: OXM +10.2%, OLLI +9.2%, PI +7.9%, NTEC +5.1%, SMTC +1.9%, APOP+1.8%, GEF +1.5%
M&A news:
- CYNA +114.6% (Cynapsus Therapeutics to be acquired by Sunovion Pharmaceuticals for $40.50/share in cash, or approximately $624 mln )
- ARMH +1.5% (progress in merger with Softbank, High Court of Justice in England and Wales has today sanctioned the scheme of arrangement)
- TWTR +1.4% (continued strength after M&A speculation began yesterday)
Select EU financial related names showing strength: LYG +4%, DB +3.7%, HSBC +2.9%, CS +2.7%, BBVA +2.6%, ING+2.2%, PUK +2.1%, SAN +2%, RBS +1.9%
Select metals/mining stocks trading higher: RIO +1.8%, BBL +1.4%, MT +1.4%, DRD +0.8%, BHP +0.6%
Select Macau gaming names showing strength after Macau gaming revs released overnight: MPEL +4.9%, WYNN+4.7%, MGM +2.8%, LVS +2.6%, .
Other news:
Select metals/mining stocks trading higher: RIO +1.8%, BBL +1.4%, MT +1.4%, DRD +0.8%, BHP +0.6%
Select Macau gaming names showing strength after Macau gaming revs released overnight: MPEL +4.9%, WYNN+4.7%, MGM +2.8%, LVS +2.6%, .
Other news:
- VKTX +11.9% (announces the presentation of data from a Phase 1 trial of VK5211 at the 5th Fragility Fracture Network Global Congress 2016 )
- CLNE +9.2% (announces multiple contract awards, including a multi-year contract for Washington Metropolitan Area Transit Authority)
- SPU +6.6% (following 40%+ move higher), ARRY +5% (FDA has accepted its New Drug Applicatio for binimetinib)
- CHTR +4.3% (to join the S&P 500), NCLH +4.1% (Pres/CEO disclosed purchase of 83498 shares, worth total of more than $3 mln )
- ZFGN +3.7% (CEO/Pres disclosed purchase of 10000 shares, worth total of $30K)
- NVCR +3.3% (announces that data showing Tumor Treating Fields in combination with paclitaxel is therapeutically effective against ovarian cancer cells)
- CASC +2.6% (announces US approval of nonproprietary name 'tucatinib' for ONT-380 - co's lead product candidate for the treatment of advanced metastatic HER2+ breast cancer)
Analyst comments:
- INVN +3.5% (resumed with a Buy at ROTH Capital)
- OA +1.5% (initiated with a Buy at Deutsche Bank)